CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded ...

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that ...

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

CRISPR-Cas9 is a gene-editing tool that allows scientists to make precise changes to an organism’s DNA. In plants, the ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

While commercial uptake by patients still lags and a recent court decision rekindles a legal battle, clinical successes ...